Compare Organon & Co. Common Stock (OGN) vs PACCAR Inc. Common Stock (PCAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PACCAR Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while PACCAR Inc. Common Stock trades at $109.43 (market cap $57.14B). The key difference: PACCAR Inc. Common Stock is far larger — about 15.8× Organon & Co. Common Stock's market cap, and PACCAR Inc. Common Stock pays the higher dividend (1.29%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PACCAR Inc. Common Stock for 6 Days on average.
| OGN | PCAR | |
|---|---|---|
Market Cap | $3.61B | $57.14B |
Volume | 1,808,049 | 2,748,310 |
Sector | Health | Industrials |
52-Week High | $13.81 | $138.21 |
52-Week Low | $5.70 | $94.15 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.03B | $63.00B |
Dividend Yield | 0.58% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PACCAR (PCAR) trades at $107.98, down 0.14% with bearish technical signals but strong fundamentals including 9% net income margin and 12.76% ROE. Recent earnings beat expectations in Q2 2026 with $1.43 EPS versus $1.36 expected. The company maintains stable cash flows with $4.3B operating cash flow projected for 2026 and recently declared a $0.35 quarterly dividend payable December 2026.
PCAR presents a mixed outlook with Wall Street consensus price target of $134.83 suggesting 25% upside potential, though technical indicators show bearish momentum. Key risks include sector sensitivity to interest rates and industrial cyclicality, while opportunities lie in the company's strong profitability metrics and defensive non-trucking segments representing over 60% of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PACCAR Inc. Common Stock
PACCAR designs and manufactures heavy-duty trucks under brands including Peterbilt, Kenworth, and DAF. It also provides parts, financial services, and technology for commercial vehicles.
Read more on PCAR →
